이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

건강한 남성 피험자에서 단일 경구 용량의 BI 425809를 단독으로 또는 이트라코나졸의 다중 경구 용량과 병용하여 투여했을 때의 상대적 생체이용률

2026년 7월 9일 업데이트: Boehringer Ingelheim

건강한 남성 대상자에서 단일 경구 용량의 BI 425809를 단독으로 또는 이트라코나졸의 다중 경구 용량과 병용하여 투여했을 때의 상대적 생체이용률(개방 라벨, 2기간, 고정 시퀀스 시험)

To investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI 425809 in healthy male subjects

연구 개요

상태

완전한

정황

연구 유형

중재적

등록 (실제)

16

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Biberach, 독일
        • 1346.10.1 Boehringer Ingelheim Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

남성

설명

Inclusion criteria:

  • Healthy male subjects according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
  • Age of 18 to 50 years (incl.)
  • Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria:

  • Any finding in the medical examination (including BP, PR or ECG) is deviating from normal and judged as clinically relevant by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
  • Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 halflives of the respective drug prior to administration of trial medication
  • Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial or that might prolong the QT/QTc interval
  • Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two month after the trial completion. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive for at least two month prior trial participation)
  • Known fructose intolerance, glucose-galactose malabsorption, or saccharose-isomaltase deficiency
  • History of relevant liver diseases such as disturbance of liver function, jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver tumours
  • Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening examination

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment R (BI 425809 alone) then Treatment T (BI 425809 + Itraconazole)

Treatment R: Subjects were administered single dose of 25 milligram (mg) BI 425809 (tablet) on Day 1.

Treatment was administered orally with 240 mL of water after administration of a standardised breakfast. Treatment T: Subjects underwent 10 days of itraconazole (capsules) treatment (first day 200 mg itraconazole twice daily, followed by 9 days 200 mg itraconazole once daily) combined with a single dose of 25 mg BI 425809 (tablet) on the fourth day of the itraconazole treatment (1 h after the itraconazole administration).

Treatments were administered orally with 240 mL of water after administration of a standardised breakfast or dinner. The BI 425809 single doses of treatments R and T were separated by a washout period of at least 16 days.

single dose BI 425809 tablet

다른 이름들:
  • 아이클레퍼틴

multiple doses of Itraconazole capsules

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 167 h (AUC0-167)
기간: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

AUC0-167 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 167 h);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
기간: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

Cmax (maximum measured concentration of the analyte in plasma);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

2차 결과 측정

결과 측정
측정값 설명
기간
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
기간: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Boehringer Ingelheim, Boehringer Ingelheim

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2015년 1월 29일

기본 완료 (실제)

2015년 3월 24일

연구 완료 (실제)

2015년 3월 24일

연구 등록 날짜

최초 제출

2015년 1월 15일

QC 기준을 충족하는 최초 제출

2015년 1월 15일

처음 게시됨 (추정된)

2015년 1월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 9일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 1346.10
  • 2014-004855-29 (EudraCT 번호: EudraCT)
  • 2014 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization).

For more details refer to:

https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다